¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cancer, basal cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell acanthoma
    ¹Ù´ÚÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, ±âÀúÆíÆò±Ø¼¼Æ÷Á¾
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • blood cell separator
    Ç÷±¸ºÐ¸®±â
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • cell bank
    ¼¼Æ÷ÀºÇà
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
  • cell
    ¼¼Æ÷
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Schwann cell tumor
    ½´¹Ý¼¼Æ÷Á¾¾ç
  • Schwann s cell
    ½´¹Ý¼¼Æ÷.
  • Sertoli cell
    ½áÅ丮 ¼¼Æ÷
  • Sertoli cell only syndrome
    ½áÅ丮 ¼¼Æ÷ ÁõÈıº
  • Sezary cell
    ¼¼ÀÚ¸®¼¼Æ÷
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • T cell activating factor
    T¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • T cell cooperation
    T¼¼Æ÷Çùµ¿
  • T cell deficiency
    T¼¼Æ÷°áÇÌ
  • T cell factor (TCF)
    T¼¼Æ÷
  • T cell growth factor (TCGF, IL-2)
    T¼¼Æ÷ Áõ½ÄÀÎÀÚ
  • T cell hybridoma
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • T cell immunity
    T¼¼Æ÷¸é¿ª
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • T cell lymphoma
    T¼¼Æ÷¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • medullary cancer
    ¼öÁú¼º¾Ï(Ëà̤ËÛËâ).
  • metastatic cancer
    ÀüÀ̼º ¾Ï(¡­äß).
  • metastatic cancer
    ÀüÀ̼º ¾Ï(¡­äß)
  • mucinoid cancer
    Á¡¾×¼º ¾Ï(Á¡¾×¼º¾Ï).
  • mucinoid cancer
    Á¡¾×¼º ¾Ï(ïÄäûàõäß).
  • mule spinner s cancer
    ¸é¹æÀû°ø¾Ï(ËÎËÑËø Ë­Ëâ).
  • mule spinner s cancer
    ¸é¹æÀû°ø¾Ï(ØúÛ·îà Íïäß).
  • noma =water cancer
    ¼ö¾Ï(â©äß) ±«Àú¼º ±¸³»¿°(ÎÕîÅàõ Ï¢Ò®æú)
  • occult cancer
    ÀáÀç¾Ï.
  • occult gastric cancer
    ÀáÀçÀ§¾Ï.
  • occupational cancer
    Á÷¾÷¾Ï(̤Ëâ ).
  • oral cancer
    ±¸°­¾Ï
  • oral cancer
    ±¸°­¾Ï(Ϣ˷ ).
  • oral cancer
    ±¸°­¾Ï(Ϣ˷äß)
  • osteolytic cancer
    °ñ¿ëÇØ¼º ¾Ï.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Multilocular fat cell
    ¹µÄ­Áö¹æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù¹æ¼ºÁö¹æ¼¼Æ÷
  • Multinuclear giant cell
    ¹µÇÙ°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÙÇÙ¼º°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Taste cell
    ¹Ì°¢¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì°¢¼¼Æ÷
  • Undifferentiated cell
    ¹ÌºÐÈ­¼¼Æ÷
    [¿¾ ¿ë¾î] ¹ÌºÐÈ­¼¼Æ÷
  • Microvillous epithelial cell
    ¹Ì¼¼À¶¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ð»óÇǼ¼Æ÷
  • Microvillous cuboidal mesothelial cell
    ¹Ì¼¼À¶¸ðÀÔ¹æÁßÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ðÀÔ¹æÁßÇǼ¼Æ÷
  • Microplica epithelial cell
    ¹Ì¼¼ÁÖ¸§»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼ÁÖ¸§»óÇǼ¼Æ÷
  • Nonfenestrated endothelial cell
    ¹Îâ³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹«Ã¢³»ÇǼ¼Æ÷
  • Basket cell
    ¹Ù±¸´Ï¼¼Æ÷
    [¿¾ ¿ë¾î] ³ó¼¼Æ÷
  • Outer pillar cell
    ¹Ù±ù±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁÖ¼¼Æ÷
  • Outer sustentacular cell
    ¹Ù±ù¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁöÁÖ¼¼Æ÷
  • Outer phalangeal cell of Deiters
    ¹Ù±ù¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÁö»ó¼¼Æ÷
  • Outer hair cell
    ¹Ù±ùÅм¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜÀ¯¸ð¼¼Æ÷
  • Fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó±Ù»óÇǼ¼Æ÷
  • Fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó³»ÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • separation cell
    ºÐ¸®½Ç(ÝÂ×îãø)
  • sickle cell
    ³´¼¼Æ÷(á¬øà)
  • sickle cell anemia
    ³´¼¼Æ÷(á¬øà)ºóÇ÷(Þ¸úì)
  • sickle cell disease
    ³´¼¼Æ÷(á¬øà)Áúȯ(òðü´)
  • sickle cell hemoglobin
    ³´¼¼Æ÷(á¬øà)È÷¸ð±Û·Îºó
  • sickle cell trait
    ³´¼¼Æ÷(á¬øà)¼ºÇâ(àõú¾)
  • single-cell protein
    ´Ü¼¼Æ÷ ´Ü¹éÁú(Ó¤á¬øàÓ±ÛÜòõ)
  • somatic cell
    ü¼¼Æ÷(ô÷á¬øà)
  • somatic cell genetic engineering
    ü¼¼Æ÷ À¯Àü°øÇÐ(ô÷á¬øàë¶îîÍïùÊ)
  • somatic cell hybrid
    ü¼¼Æ÷(ô÷á¬øà) Æ¢±â
  • suppressor T cell
    ¾ï¾Ð(åääâ) T ¼¼Æ÷(á¬øà)
  • synthetic boundary cell
    ÇÕ¼º °æ°è½Ç (ùêà÷ÌÑÍ£ãø)
  • target cell
    Ç¥Àû¼¼Æ÷ (øöîÜá¬øà)
  • T cell
    T ¼¼Æ÷(á¬øà)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
HRC hereditary renal cancer; high-resolution chromatography; horse red cell; human rights committee
NSCLC non-small-cell lung cancer
PLCC primary liver cell cancer
SCF Skin Cancer Foundation; stem cell factor; subcostal frontal [view]
SK seborrheic keratosis; senile keratosis; Sloan-Kettering [Institute for Cancer Research]; spontaneous...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
SCCHN squamous cell cancer of the head and neck
TCC transitional cell cancer
A.G.C. Advanced Gastric Cancer
ATBC Alpha-Tocopherol Beta-Carotene Cancer Prevention
ACS American Cancer Society
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • angiotropic intravascular large cell lymphoma
    Ç÷°ü ¿µ¾ç¼º Ç÷°ü³» ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell lymphoma
    B ¼¼Æ÷ ¸²ÇÁÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾ Áß¿¡¼­ ¥ì¼â, DR Ç׿ø, Leu-10ÀÇ B ¸²ÇÁ±¸ Ç¥½ÃÀÚ°¡ Áõ¸íµÈ ¸²ÇÁÁ¾ÀÌ´Ù. Áõ¸íµÈ Ç¥½ÃÀÚ´Â °³°³ÀÇ Áõ·Ê¿¡ µû¶ó ´Ù¸£°í ¥ì+, DR+ Leu-10+ÀÇ ÀüÇüÀûÀÎ ¿¹·ÎºÎÅÍ DR ³»Áö Leu-10¸¸ÀÌ ¾ç¼ºÀÎ Áõ·Ê¿¡ À̸£±â±îÁö ±× º¯È­´Â ´Ù¾çÇÏ´Ù. ÇüÅÂÀûÀÎ ºÐ·ù¿¡ ÀÇÇÑ °áÀý¼º ¸²ÇÁÁ¾, ¸²ÇÁÇüÁú ¼¼Æ÷¼º ¸²ÇÁÁ¾, ¹èÁ᫐ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾ µîÀÌ B¼¼Æ÷ ¸²ÇÁÁ¾¿¡ ¼ÓÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
bovine cancer eye A malignant squamous cell carcinoma of cattle, especially the Hereford breed, that originates in the conjunctival mucous membranes or the surrounding skin; it occurs principally in range cattle having unpigmented skin around the eye and living in regions of intense sunlight.
(05 Mar 2000)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
breast cancer <oncology> The uncontrolled growth of malignant breast tissue.
Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group.
Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer.
Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography.
WWW: cancerNET document for patients
WWW: cancerNET document for clinicians
(05 Jan 1998)
breast cancer susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
buyo cheek cancer betel cancer
cancer <oncology> The first historical description of this condition was in relation to breast carcinoma.
This is now a general term for more than 100 diseases that are characterised by uncontrolled, abnormal growth of cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body.
(18 Nov 1997)
cancer antigen 125 test Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis.
(05 Mar 2000)
cancer, bladder Cancer of the organ responsible for temporarily holding urine after it leaves the kidneys. The most common warning sign of cancer in the bladder (the hollow organ in the lower abdomen that stores urine) is blood in the urine. The diagnosis of bladder cancer is supported by findings of the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam).
(12 Dec 1998)
cancer bodies Discrete, acidophilic or amphophilic, hyaline body's of various shapes and sizes, occurring in the cytoplasm of some of the neoplastic cells and also extracellularly in the stroma of various carcinomas and sarcomas; formerly regarded by some observers as parasitic causal agents, but now thought to be products of cell necrosis (apoptosis).
(05 Mar 2000)
cancer, bone Cancer of the skeleton. Cancers that begin in bone are rare but it is not unusual for cancers to spread (metastasize) to bone from other parts of the body. This is not called bone cancer, but is named for the organ or tissue in which the cancer begins. Pain is the most frequent symptom of cancer of the bone. Diagnosis of cancer of the bone is supported by findings of the medical history and examination, blood and X-ray tests and confirmed with a biopsy.
(12 Dec 1998)
cancer, brain Cancer of the central information processing centre of the body. Tumours in the brain can be malignant or benign and can occur at any age. Primary brain tumours initially form in the brain tissue. Secondary brain tumours are cancers that have spread to the brain tissue (metastasized) from elsewhere in the body.
(12 Dec 1998)
cancer, breast Cancer of the tissue containing or involving the milk glands (mammary tissue). Breast cancer is diagnosed with self- and physician- examination of the breasts, mammography, ultrasound testing, and biopsy. There are many types of breast cancer that differ in their capability of spreading to other body tissues (metastasis). Treatment of breast cancer depends on the type and location of the breast cancer, as well as the age and health of the patient. The American Cancer Society recommends that a woman should have a baseline mammogram between the ages of 35 and 40 years. Between 40 and 50 years of age mammograms are recommended every other year. After age 50 years, yearly mammograms are recommended.
(12 Dec 1998)
cancer, breast, familial A number of factors have been identified that increase the risk of breast cancer. One of the strongest of these risk factors is the history of breast cancer in a relative. About 15-20% of women with breast cancer have such a family history of the disease, clearly reflecting the participation of inherited (genetic) components in the development of some breast cancers. Dominant breast cancer suceptibility genes, including BRCA1 and BRCA2, appear responsible for about 5% of all breast cancer.
(12 Dec 1998)
cancer, breast, susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
cancer care facilities Institutions specializing in the care of cancer patients.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á